Castle Biosciences (CSTL)
US Market

Castle Biosciences (CSTL) Stock Price & Analysis


CSTL Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$15.58 - $48.40
Previous Close$28.3
Average Volume (3M)175.77K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$265.98M
Total Debt (Recent Filing)$13.44M
Price to Earnings (P/E)-13.8
Next EarningsMar 14, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-2.06
Shares Outstanding26,351,576
Standard Deviation0.18
10 Day Avg. Volume122,310
30 Day Avg. Volume175,770
Price to Book (P/B)2.54
Price to Sales (P/S)7.35
Price to Cash Flow (P/CF)230.60
P/FCF Ratio-10.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside69.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $15.58 and its highest was $48.40 in the past 12 months.
    What is Castle Biosciences’s market cap?
    Currently, no data Available
    When is Castle Biosciences’s upcoming earnings report date?
    Castle Biosciences’s upcoming earnings report date is Mar 14, 2023 which is in 38 days.
      How were Castle Biosciences’s earnings last quarter?
      Castle Biosciences released its earnings results on Nov 02, 2022. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.881 by $0.111.
        Is Castle Biosciences overvalued?
        According to Wall Street analysts Castle Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Castle Biosciences pay dividends?
          Castle Biosciences does not currently pay dividends.
          What is Castle Biosciences’s EPS estimate?
          Castle Biosciences’s EPS estimate is -$0.84.
            How many shares outstanding does Castle Biosciences have?
            Castle Biosciences has 26,351,576 shares outstanding.
              What happened to Castle Biosciences’s price movement after its last earnings report?
              Castle Biosciences reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.881. Following the earnings report the stock price went down -2.019%.
                Which hedge fund is a major shareholder of Castle Biosciences?
                Among the largest hedge funds holding Castle Biosciences’s share is Graham Capital Management, L.P.. It holds Castle Biosciences’s shares valued at 1M.


                  Castle Biosciences Stock Smart Score

                  The Castle Biosciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Castle Biosciences

                  Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The company offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Enhabit, Inc
                  InnovAge Holding

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis